Información del producto
MK-0941 is a potential therapeutic for the treatment of type 2 diabetes. It is a novel, orally active, small molecule that has been shown to reduce blood glucose levels in preclinical models. MK-0941 targets pancreatic and hepatic steatosis by inhibiting the uptake of triglycerides from plasma into these tissues. MK-0941 also increases insulin sensitivity in vitro and in vivo. This drug has been studied as monotherapy at doses of 0.1, 1, or 10 mg/kg and as combination therapy with metformin at doses of 5 or 25 mg/kg in db/db mice and wild-type mice. The study drug was well tolerated up to 10 mg/kg without any adverse effects on body weight or food intake observed.
MK-0941 has shown promising results in lowering blood glucose levels and improving insulin sensitivity when administered alone or in combination with metformin at high doses.
Propiedades químicas
Consulta técnica sobre: 3D-MVB91697 MK-0941
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
